Elanco Tiergesundheit Ag v. The Assistant Controller Of Patents And Designs

In the high-stakes world of pharmaceutical and biotech patents, inventors often assume the battle will be fought on scientific merit — novelty, inventive step, and the boundaries of prior art. But sometimes, the case never reaches that battlefield. Sometimes, the fight is over paperwork, timelines, and procedural compliance. The appeal of Elanco Tiergesundheit Ag before the High Court is a striking reminder that even a strong patent application can be derailed by the unglamorous mechanics of appellate procedure.

Elanco Tiergesundheit Ag, a player in the animal health industry, filed a patent application (No. 3679/DELNP/2015) titled 'Preparation of Live Vaccines.' The application was examined by the Assistant Controller of Patents and Designs, who ultimately rejected it on the grounds of lack of novelty and lack of inventive step — two of the most fundamental hurdles any patent must clear. Unsurprisingly, Elanco chose to appeal the rejection. But before the court could dive into the scientific and legal merits of whether the live vaccine preparation was truly novel and non-obvious, it had to deal with a stack of preliminary applications filed by the parties.

The court's docket was crowded with procedural skirmishes before the substantive patent dispute could even be addressed. Elanco and the patent authorities each brought applications seeking exemption from filing affidavits, permission to file additional documents, and — most critically — condonation of delay in filing the appeal. The legal friction here was not about vaccines or biology; it was about whether the appeal had been brought within the prescribed time limits, and whether the parties should be excused from strict procedural requirements. The petitioner had to demonstrate sufficient cause for any delay, while the respondent pushed back on procedural leniency. The substantive arguments about novelty and inventive step — the very heart of the patent rejection — were forced to wait on the sidelines.

As of the hearing on 7 October 2022, the matter remained pending before the court. The court had not yet issued a final ruling on either the procedural applications or the underlying patent rejection. However, the proceedings highlighted a critical legal principle: delays in filing appeals can be condoned if sufficient cause is shown, drawing parallels to the standards applied under Section 5 of the Limitation Act, 1963. The outcome of the substantive patent dispute — whether Elanco's live vaccine preparation truly lacked novelty and inventive step — remained unresolved.

For founders, inventors, and IP professionals, this case is a powerful lesson: never underestimate procedural compliance. A groundbreaking invention can be delayed, derailed, or even lost if appeal timelines are missed or if supporting documents and affidavits are not filed correctly and on time. Treat procedural deadlines with the same seriousness as you treat the science behind your invention. Build internal checklists for patent filings, track limitation periods meticulously, and consult IP counsel early to avoid the trap of having your strongest technical arguments never heard because the court is still sorting out paperwork.